These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28024124)

  • 1. Developing therapies to treat hepatitis C infection in post-liver transplant recipients.
    McCarty TR; Lim JK
    Expert Opin Pharmacother; 2017 Feb; 18(2):165-174. PubMed ID: 28024124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
    Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Post-Liver Transplant Recurrence of Hepatitis C.
    Taylor J; Cox-North P; Landis CS
    Drugs; 2016 Dec; 76(18):1711-1717. PubMed ID: 27878476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
    Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
    Ueda Y; Uemoto S
    Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hepatitis C patients with decompensated liver disease.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus and liver transplantation: where do we stand?
    Burra P; De Martin E; Zanetto A; Senzolo M; Russo FP; Zanus G; Fagiuoli S
    Transpl Int; 2016 Feb; 29(2):135-52. PubMed ID: 26199060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Njei B; McCarty TR; Fortune BE; Lim JK
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
    Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
    Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
    J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of HCV transplant patients with triple therapy.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2014 Feb; 34 Suppl 1():46-52. PubMed ID: 24373078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of new treatment options for hepatitis C virus infection in liver transplantation.
    Righi E; Londero A; Carnelutti A; Baccarani U; Bassetti M
    World J Gastroenterol; 2015 Oct; 21(38):10760-75. PubMed ID: 26478668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.
    Kwo PY; Badshah MB
    Curr Opin Organ Transplant; 2015 Jun; 20(3):235-41. PubMed ID: 25944238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C treatment in patients on the liver transplant waiting list.
    Verna EC; O'Leary JG
    Curr Opin Organ Transplant; 2015 Jun; 20(3):242-50. PubMed ID: 25944239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
    World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and management of hepatitis C in liver transplant recipients.
    Chan SE; Rosen HR
    Clin Infect Dis; 2003 Sep; 37(6):807-12. PubMed ID: 12955642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.